NAPSR News: AstraZeneca and Eli Lilly start Phase II/III trial for new Alzheimer’s treatment

WASHINGTON - Dec. 1, 2014 - PRLog -- AstraZeneca and Eli Lilly and Company have recruited their first patient for the AMARANTH Phase II/III study to assess an oral beta secretase cleaving enzyme (BACE) inhibitor called AZD3293 which is currently being developed as a treatment option for Alzheimer’s disease. The study will evaluate the safety and efficacy of the investigational treatment compared with placebo .

Based on Phase 1 studies, AZD3293, also known as LY3314814 reduced the levels of amyloid-beta in the cerebro-spinal fluid of Alzheimer’s patients and healthy volunteers. The accumulation of amyloid plaque in the brain contributes to the progression of Alzheimer’s disease. By inhibiting the BACE (enzyme linked to the development of beta-amyloid), this may prevent the formation of amyloid plaque thus slowing the disease progression.

Samantha Budd, Vice President and Head of Translational Science in AstraZeneca’s Neuroscience Innovative Medicines Unit said: “There is a critical need to develop new medicines that can change the course of Alzheimer’s disease. We believe that BACE inhibitors have the potential to target one of the key drivers of this devastating disease. Together with Lilly, we have unique expertise that will allow us to evaluate the potential of AZD3293 as a treatment for Alzheimer’s patients.”

“We’re excited to take this important next step in Lilly’s continuing efforts to make life better for so many people and families affected by Alzheimer’s disease,” said Phyllis Ferrell, global brand development leader for Alzheimer’s disease at Lilly. “Our AstraZeneca partners share our determination to find answers for this condition that shatters lives. We’re pleased that the first patient enrollment in AMARANTH comes less than three months since we announced our alliance.”

The alliance between AstraZeneca and Eli Lilly aims to focus on the development and commercialization of AZD3293/LY3314814. In accordance with the terms and agreement,  Lilly will head the research and development process from AstraZeneca’s Neuroscience Innovative Medicines Unit and AstraZeneca will be responsible for manufacturing. Both companies will share all future costs equally for development and commercialization, and net global revenues post-launch.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!

With such industry leaders paving the way on identifying beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently. The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/